Disclosures for "Treatment with XPro1595 of the ‘ARIA-at-risk’ Population of MINDFuL: Subpopulation Results of the 6-month Phase 2 Trial Targeting Neuroinflammation in Early Alzheimer’s Disease "
-
Dr. Staats has received personal compensation for serving as an employee of INmune Bio. Dr. Staats has or had stock in INmune Bio.
-
Author has nothing to disclose
-
Author has nothing to disclose